← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Titan Pharmaceuticals, Inc.
South San Francisco, CA
$17,983,051
Total funding
4
Grants
Funding over time
peak $6.1M · FY2009–19$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$17,983,051 · 4
By mechanism
UG3$8,741,592 · 1
RC2$7,586,848 · 1
R44$1,159,611 · 1
R43$495,000 · 1
Investigators at Titan Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Nalmefene Implant for the Long-Term Treatment of Opioid Use Disorder$6,075,000
UG3 · FY2019 · DA
A Six-Month, RCT of Probuphine Safety and Efficacy in Opioid Addiction$5,564,010
RC2 · FY2009 · DA
Nalmefene Implant for the Long-Term Treatment of Opioid Use Disorder$2,666,592
UG3 · FY2018 · DA
A Six-Month, RCT of Probuphine Safety and Efficacy in Opioid Addiction$2,022,838
RC2 · FY2010 · DA
SPHERAMINE: A CELL-BASED THERAPY FOR PARKINSON'S DISEASE$774,379
R44 · FY2000 · NS
SPHERAMINE: A CELL-BASED THERAPY FOR PARKINSON'S DISEASE$385,232
R44 · FY2001 · NS
Long-term non-fluctuating dopamine agonist delivery for Parkinson's disease$300,000
R43 · FY2010 · NS
Long-term non-fluctuating dopamine agonist delivery for Parkinson's disease$195,000
R43 · FY2011 · NS